Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents

Liver International

Volumn 34, Issue 8, 2014, Pages 1198-1206

  Alavi, Maryam ^a   Raffa, Jesse D ^b   Deans, Gregory D ^c   Lai, Calvin ^d   Krajden, Mel ^e   Dore, Gregory J ^a   Tyndall, Mark W ^f   Grebely, Jason ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d ST PAUL S HOSPITAL   (Canada)

^e BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^f UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Drug use; Hepatitis C virus; People who inject drugs; Treatment uptake

Indexed keywords

COCAINE; HEPATITIS C ANTIBODY; INTERFERON; METHAMPHETAMINE; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG USE; ETHNICITY; FEMALE; HEALTH SURVEY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACY; URBAN POPULATION; CANADA; CITY; MIDDLE AGED; PARTICIPATORY RESEARCH; PATIENT ATTITUDE; RETROSPECTIVE STUDY; RISK; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

ADULT; BRITISH COLUMBIA; CITIES; COHORT STUDIES; COMMUNITY-BASED PARTICIPATORY RESEARCH; DRUG USERS; FEMALE; HEPATITIS C; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PATIENT ACCEPTANCE OF HEALTH CARE; RETROSPECTIVE STUDIES;

EID: 84905678530     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12370     Document Type: Article

References (51)

1. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nature Reviews Gastroenterology Hepatology 2013; 10: 553-62.
2. Thein H-H, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48: 418-31.
3. Grebely J, Tyndall MW. Management of HCV and HIV infections among people who inject drugs. Current Opinion in HIV & AIDS 2011; 6: 501-7.
4. el Saadany S, Coyle D, Giulivi A, Afzal M. Economic burden of hepatitis C in Canada and the potential impact of prevention. Results from a disease model. European Journal of Health Economics 2005; 6: 159-65.
5. Kielland KB, Skaug K, Amundsen EJ, Dalgard O. All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study. J Hepatol 2013; 58: 31-7.
6. Grebely J, Dore GJ. What is killing people with hepatitis C virus infection? Semin Liver Dis 2011; 31: 331-9.
7. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-93.
8. Dore GJ. The changing therapeutic landscape for hepatitis C. The Medical Journal of Australia 2012; 196: 629-32.
9. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009; 49: 561-73.
10. Dimova RB, Zeremski M, Jacobson IM, et al. Determinants of Hepatitis C Virus Treatment Completion and Efficacy in Drug Users Assessed by Meta-analysis. Clin Infect Dis 2013; 56: 806-16.
11. Bruggmann P. Accessing Hepatitis C patients who are difficult to reach: it is time to overcome barriers. J Viral Hepat 2012; 19: 829-35.
12. Lettmeier B, Muhlberger N, Schwarzer R, et al. Market uptake of new antiviral drugs for the treatment of hepatitis C. J Hepatol 2008; 49: 528-36.
13. Volk ML, Tocco R, Saini S, Lok ASF. Public health impact of antiviral therapy for hepatitis C in the United States.[Erratum appears in Hepatology. 2010 Feb;51(2):725]. Hepatology 2009; 50: 1750-5.
14. Butt AA, Justice AC, Skanderson M, et al. Rate and predictors of treatment prescription for hepatitis C. Gut 2007; 56: 385-9.
15. NCHECR. HIV/AIDS, Viral Hepatitis and Sexually Transmissible Infections in Australia Annual Surveillance Report 2009. National Centre in HIV Epidemiology and Clinical Research (NCHECR), The University of New South Wales, Sydney, 2009.
16. Grebely J, Raffa JD, Lai C, et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepatitis 2009; 16: 352-8.
17. Mehta SH, Genberg BL, Astemborski J, et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008; 33: 126-33.
18. kramer JR, Kanwal F, Richardson P, et al. Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study. Am J Gastroenterol 2011; 106: 483-91.
19. Grebely J, Bryant J, Hull P, et al. Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales Australia. J Viral Hepatitis 2011; 18: e104-16.
20. Gidding HF, Law MG, Amin J, et al. Predictors of deferral of treatment for hepatitis C infection in Australian clinics. Med J Aust 2011; 194: 398-402.
21. Razavi H, Estes C, Pasini K, Gower E, Hindman S. HCV treatment rate in select european countries in 2004-2010. J Hepatol 2013; 58: S22-3.
22. European Association for the Study of the L. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-64.
23. Smith BD, Jorgensen C, Zibbell JE, Beckett GA. Centers for Disease Control and Prevention initiatives to prevent hepatitis C virus infection: a selective update. Clin Infect Dis 2012; 55 Suppl 1: S49-53.
24. Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the study of liver D. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
25. Seeff LB, Hoofnagle JH. National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology 2002; 36(5 Suppl 1): S1-2.
26. Sherman M, Bain V, Villeneuve J-P, et al. The management of chronic viral hepatitis: a Canadian consensus conference 2004. Canadian Journal of Gastroenterology 2004; 18: 715-28.
27. Lindenburg CEA, Lambers FAE, Urbanus AT, et al. Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project. Eur J Gastroenterol Hepatol 2011; 23: 23-31.
28. Grebely J, Knight E, Genoway KA, et al. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. Eur J Gastroenterol Hepatol 2010; 22: 270-7.
29. Charlebois A, Lee L, Cooper E, Mason K, Powis J. Factors associated with HCV antiviral treatment uptake among participants of a community-based HCV programme for marginalized patients. J Viral Hepatitis 2012; 19: 836-42.
30. Sylvestre DL, Clements BJ. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Eur J Gastroenterol Hepatol 2007; 19: 741-7.
31. Arora S, Thornton K, Murata G, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med 2011; 364: 2199-207.
32. Magnani R, Sabin K, Saidel T, Heckathorn D. Review of sampling hard-to-reach and hidden populations for HIV surveillance. Aids 2005; 19: S67-72.
33. Myles A, Mugford GJ, Zhao J, Krahn M, Wang PP. Physicians' attitudes and practice toward treating injection drug users infected with hepatitis C virus: results from a national specialist survey in Canada. Canadian Journal of Gastroenterology 2011; 25: 135-9.
34. Kanwal F, Hoang T, Spiegel BMR, et al. Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors. Hepatology 2007; 46: 1741-9.
35. Hill WD, Butt G, Alvarez M, Krajden M. Capacity enhancement of hepatitis C virus treatment through integrated, community-based care. Canadian Journal of Gastroenterology 2008; 22: 27-32.
36. Robaeys G, Grebely J, Mauss S, et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Clin Infect Dis 2013; 57(Suppl 2): S129-37.
37. Public Health Agency of Canada. Epi-Update: Hepatitis C virus (HCV) among Aboriginal people surveyed by three national enhanced surveillance systems in Canada. Centre for Communicable Disease and Infection Control, Ottawa, 2010.
38. Resnick I, Brener L. Hepatitis C and the Aboriginal population. National Centre in HIV Social Research, The University of New South Wales, Australia, 2010.
39. Pearlman BL. Hepatitis C virus infection in African Americans. Clin Infect Dis 2006; 42): 82-91.
40. Cheung RC, Currie S, Shen H, et al. Chronic hepatitis C in Latinos: natural history, treatment eligibility, acceptance, and outcomes. Am J Gastroenterol 2005; 100: 2186-93.
41. Spittal PM, Pearce ME, Chavoshi N, et al. The Cedar Project: high incidence of HCV infections in a longitudinal study of young Aboriginal people who use drugs in two Canadian cities. BMC Public Health 2012; 12: 632.
42. Lemstra M, Rogers M, Thompson A, Moraros J, Buckingham R. Risk indicators associated with injection drug use in the Aboriginal population. AIDS Care 2012; 24: 1416-24.
43. Buxton JA, Yu A, Kim PH, et al. HCV co-infection in HIV positive population in British Columbia Canada. BMC Public Health 2010; 10: 225.
44. Cooper CL, Bailey RJ, Bain VG, et al. Outcomes of peginterferon alpha-2a and ribavirin hepatitis C therapy in Aboriginal Canadians. Canadian Journal of Gastroenterology 2008; 22: 677-80.
45. Bini EJ, Brau N, Currie S, et al. Prospective multicenter study of eligibility for antiviral therapy among 4, 084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol 2005; 100: 1772-9.
46. Fischer B, Rehm J, Patra J, et al. Crack across Canada: comparing crack users and crack non-users in a Canadian multi-city cohort of illicit opioid users. Addiction 2006; 101: 1760-70.
47. Iritani BJ, Hallfors DD, Bauer DJ. Crystal methamphetamine use among young adults in the USA. Addiction 2007; 102: 1102-13.
48. Grebely J, Oser M, Taylor LE, Dore GJ. Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels. J Infect Dis 2013; 207(Suppl 1): 19-25.
49. Craib KJ, Spittal PM, Wood E, et al. Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver. Can Med Assoc J 2003; 168: 19-24.
50. Shield KD, Rehm J. Difficulties with telephone-based surveys on alcohol consumption in high-income countries: the Canadian example. International journal of methods in psychiatric research 2012; 21: 17-28.
51. Alavi M, Grebely J, Micallef M, et al. Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study. Clin Infect Dis 2013; 57(suppl 2): S62-9.